Development and validation of reversed phase HPLC method for determination of apremilast in bulk and pharmaceutical dosage form

https://doi.org/10.53730/ijhs.v6nS2.7491

Authors

  • Anuja Kolsure Research Scholar, Faculty of Pharmacy, (B. R. Nahata College of Pharmacy), Mandsaur University, Mandsaur -458001 (M.P), India
  • Rupesh Soni Faculty of Pharmacy, (B. R. Nahata College of Pharmacy), Mandsaur University, Mandsaur – 458001 (M.P), India
  • Mahesh Bhat Nuper Therapeutics, A division of Jain Pharmaceuticals, Pune - 411045 (M.H), India

Keywords:

apremilast, RP-HPLC, validation

Abstract

The present study describes a novel Reversed Phase High-Performance LC method for the determination and estimation of Apremilast (APR) in bulk and pharmaceutical formulation. The chromatographic separation was carried out on Agilent 1120LC Compact system with Binary gradient system connected to UV- Absorbance Detector. Acetonitrile:   (30mM) Potassium dihydrogen phosphate buffer pH adjusted to 3.0 with o-phosphoric acid (60:40 v/v), and flow rate 1.0ml/min with an injection volume of 20 μL was selected as it gave sharp symmetric peak for APL with minimal tailing and with desired elution graph.The separation was carried out at a room temperature and the eluents were observed by UV - Vis detector set at 236 nm. The retention time of APR obtained was at 4.46 minutes. The calibration curve for APR was linear (r2= 0.995) over thetested concentration range of 10 - 60 μg/ ml with LOD and LOQ of 0.93 μg/ml and 2.82μg/ml respectively. A recovery of APR in tablet formulation was observed in the range of 98.40 -100.00 %. Thus the proposed method for APR was found to be feasible for the estimation of APR in bulk as well as pharmaceutical dosage form.

Downloads

Download data is not yet available.

References

Papp, K., Cather, JC.,Rosoph, L., et al. Lancet, 2012. 380:738–746.

Ritesh P. Bhole, Sachin R. Naksakhare, Chandrakant G. Bonde., A Stability Indicating HPTLC Method for Apremilast and Identification of degradation products using MS/MS. J. Pharm. Sci. & Res. Vol. 11(5), 2019, 1861-1869.

Schett, G., Sloan, VS., Stevens, RM., et al. TherAdvMusculoskelet Dis, 2010. 2: 271–278.

Paul, C., Cather, J., Gooderham, M., et al. Br J Dermatol, 2015.173:1387–1399.

Papp, K., Reich, K., Leonardi, CL., et al. J Am AcadDermatol, 2015. 73:37–49.

SyedaKulsum, VidyaSagar G, AfreenButul, Saba Fatima, MD Sami Uddin, Method development and validation of forced degradation studies of Apremilast by using UV spectrophotometric method, world journal of pharmacy and pharmaceutical sciences, 5(6), 2016, 1595-1601.

Xiong K, Ma X, Liu L, Sun L, Zou Q. Identification, characterization and HPLC quantification of impurities in Apremilast. Publishing book journals and database, 20(2), 1997, 1-56.

Ranjith Singh, HPLC Method Development and Validation an Overview, J Pharm. 2013; 26-33 Beckett A H and Stanlake J B. Practical pharmaceutical chemistry; part two: 281-307.

Nidhi Patel, Sagarkumar Patel, DrJasminaSurati, Dr Ashok Akbari, DrDhiren Shah, Apremilast – A review of Analytical Methods Developed for API with its impurities, Pharmaceutical Formulations and Biological Matrices. International Journal of Pharmaceutical Research and Applications Volume 6, Issue 3 May - June 2021, pp: 735-755.

AnujaKolsure, Kratika Daniel, Mahesh Bhat.Development & Validation Of Rp-Hplc Method For Estimation Of Glabridin In A Novel Formulation, International Journal of Advanced Science and Technology, Vol. 29, No. 03, (2020), pp-15643-15649.

ICH Q2 (R1) Validation of analytical procedures, Text and methodology International conference on Harmonization, Geneva, 2005. 1-17.

Published

18-05-2022

How to Cite

Kolsure, A., Soni, R., & Bhat, M. (2022). Development and validation of reversed phase HPLC method for determination of apremilast in bulk and pharmaceutical dosage form. International Journal of Health Sciences, 6(S2), 9484–9493. https://doi.org/10.53730/ijhs.v6nS2.7491

Issue

Section

Peer Review Articles